Eurofins CDMO Alphora Launches AI Tool to Enhance Drug Screening

Eurofins CDMO Alphora has introduced an innovative AI-powered software platform designed to enhance high-throughput salt and co-crystal screening. This tool has been integrated as a fundamental component of the company’s solid-state screening programs, aiming to significantly reduce development timelines and associated costs.

The new software was developed in collaboration with a local university and leverages advanced machine learning techniques to predict the formation of salts and co-crystals for active pharmaceutical ingredients and their intermediates. By utilizing predictive models, the platform minimizes the reliance on trial-and-error methods traditionally employed in solid form selection.

According to Eurofins CDMO Alphora, this approach streamlines the development process, enabling faster, data-driven decision-making during the early stages of drug substance development. The company emphasizes that the integration of this AI tool is a game-changing advancement in their solid-state research and development efforts.

Supporting Comprehensive Drug Development

Eurofins CDMO Alphora’s dedicated solid-state research and development team plays a crucial role in assisting customers throughout the salt and co-crystal development process. This support includes everything from data interpretation to formulating experimental strategies. The team is also equipped to tackle a variety of challenges that extend beyond salt and co-crystal screening.

By fostering collaboration across drug substance and drug product development functions, the company provides comprehensive contract manufacturing and development solutions. Their goal is to enhance bioavailability and improve the overall performance of manufacturing processes.

The launch of the AI-driven platform reflects Eurofins CDMO Alphora’s commitment to advancing pharmaceutical development through innovative technology. As the pharmaceutical industry increasingly adopts AI tools, this development positions the company as a leader in integrating cutting-edge solutions to meet the evolving demands of drug development.

Overall, the introduction of this AI-powered software represents a significant step forward for Eurofins CDMO Alphora, enhancing its capabilities in solid-state screening and contributing to the future of efficient drug development practices. With a focus on reducing costs and timelines, the company is set to make a lasting impact in the pharmaceutical sector.